# SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

> **NCT00442572** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** PEGASYS [peginterferon alfa-2a]

## Key facts

- **NCT ID:** NCT00442572
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-03
- **Primary completion:** 2012-04-23
- **Final completion:** 2012-04-23
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442572, "SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00442572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*